Changes in hepatitis B virus DNA levels and liver function after transcatheter arterial chemoembolization of hepatocellular carcinoma

[Guest guest]

http://onlinelibrary.wiley.com/doi/10.1111/j.1872-034X.2011.00796.x/abstract

Changes in hepatitis B virus DNA levels and liver function after transcatheter

arterial chemoembolization of hepatocellular carcinoma

Xiang-Ming Lao1,2,†, Dian Wang1,†, Ming Shi1, Guipeng Liu3, Shengping Li1,

Rongping Guo1, Yunfei Yuan1, Minshan Chen1, Jinqing Li1, Yaqi Zhang1,*, Xiaojun

Lin1,*Article first published online: 29 MAR 2011

DOI: 10.1111/j.1872-034X.2011.00796.x

© 2011 The Japan Society of Hepatology

Issue

Hepatology Research

Volume 41, Issue 6, pages 553–563, June 2011

ABSTRACT

Aim:  Reports concerning changes in hepatitis B virus (HBV) status and liver

function in hepatocellular carcinoma (HCC) during or after transcatheter

arterial chemoembolization (TACE) have been rare and the results inconsistent.

The objective of this retrospective study was to evaluate these parameters in a

large cohort of HBV-related HCC patients.

Methods:  One hundred and seventy-two hepatitis B surface antigen positive HCC

patients with Child–Pugh grade A or B liver disease who underwent 228 sessions

of TACE were enrolled, and related clinical and laboratory data were analyzed.

Results:  In total, HBV reactivated in 33 (14.5%), remained stable in 152

(66.7%) and decreased in 43 (18.8%) sessions. Univariate analysis revealed that

sex and HBV DNA levels correlated with changes in HBV DNA status after TACE,

while hepatitis B e-antigen (HBeAg), prothrombin time and chemotherapeutic

agents were marginally significant factors. Multivariate analysis demonstrated

that the major factors that influenced the HBV DNA status were baseline HBV DNA

levels(P = 0.0002) and HBeAg (P = 0.0387). A comparison of the post-TACE

(30–90 days) liver function to the baseline revealed no significant

differences. The reactivation group has the highest rate of exacerbation (12.1%)

compared with the stable group (5.9%) and downregulation group (4.7%).

Conclusion:  HBV DNA changes after TACE included reactivated, decreased and

stable HBV DNA levels. Although HBV reactivation did not necessarily result in

exacerbation of liver damage and most HCC patients with Child–Pugh grade A and

B tolerated TACE well, careful post-procedure monitoring and managing is needed.

[Guest guest]

http://onlinelibrary.wiley.com/doi/10.1111/j.1872-034X.2011.00796.x/abstract

Changes in hepatitis B virus DNA levels and liver function after transcatheter

arterial chemoembolization of hepatocellular carcinoma

Xiang-Ming Lao1,2,†, Dian Wang1,†, Ming Shi1, Guipeng Liu3, Shengping Li1,

Rongping Guo1, Yunfei Yuan1, Minshan Chen1, Jinqing Li1, Yaqi Zhang1,*, Xiaojun

Lin1,*Article first published online: 29 MAR 2011

DOI: 10.1111/j.1872-034X.2011.00796.x

© 2011 The Japan Society of Hepatology

Issue

Hepatology Research

Volume 41, Issue 6, pages 553–563, June 2011

ABSTRACT

Aim:  Reports concerning changes in hepatitis B virus (HBV) status and liver

function in hepatocellular carcinoma (HCC) during or after transcatheter

arterial chemoembolization (TACE) have been rare and the results inconsistent.

The objective of this retrospective study was to evaluate these parameters in a

large cohort of HBV-related HCC patients.

Methods:  One hundred and seventy-two hepatitis B surface antigen positive HCC

patients with Child–Pugh grade A or B liver disease who underwent 228 sessions

of TACE were enrolled, and related clinical and laboratory data were analyzed.

Results:  In total, HBV reactivated in 33 (14.5%), remained stable in 152

(66.7%) and decreased in 43 (18.8%) sessions. Univariate analysis revealed that

sex and HBV DNA levels correlated with changes in HBV DNA status after TACE,

while hepatitis B e-antigen (HBeAg), prothrombin time and chemotherapeutic

agents were marginally significant factors. Multivariate analysis demonstrated

that the major factors that influenced the HBV DNA status were baseline HBV DNA

levels(P = 0.0002) and HBeAg (P = 0.0387). A comparison of the post-TACE

(30–90 days) liver function to the baseline revealed no significant

differences. The reactivation group has the highest rate of exacerbation (12.1%)

compared with the stable group (5.9%) and downregulation group (4.7%).

Conclusion:  HBV DNA changes after TACE included reactivated, decreased and

stable HBV DNA levels. Although HBV reactivation did not necessarily result in

exacerbation of liver damage and most HCC patients with Child–Pugh grade A and

B tolerated TACE well, careful post-procedure monitoring and managing is needed.

[Guest guest]

http://onlinelibrary.wiley.com/doi/10.1111/j.1872-034X.2011.00796.x/abstract

Changes in hepatitis B virus DNA levels and liver function after transcatheter

arterial chemoembolization of hepatocellular carcinoma

Xiang-Ming Lao1,2,†, Dian Wang1,†, Ming Shi1, Guipeng Liu3, Shengping Li1,

Rongping Guo1, Yunfei Yuan1, Minshan Chen1, Jinqing Li1, Yaqi Zhang1,*, Xiaojun

Lin1,*Article first published online: 29 MAR 2011

DOI: 10.1111/j.1872-034X.2011.00796.x

© 2011 The Japan Society of Hepatology

Issue

Hepatology Research

Volume 41, Issue 6, pages 553–563, June 2011

ABSTRACT

Aim:  Reports concerning changes in hepatitis B virus (HBV) status and liver

function in hepatocellular carcinoma (HCC) during or after transcatheter

arterial chemoembolization (TACE) have been rare and the results inconsistent.

The objective of this retrospective study was to evaluate these parameters in a

large cohort of HBV-related HCC patients.

Methods:  One hundred and seventy-two hepatitis B surface antigen positive HCC

patients with Child–Pugh grade A or B liver disease who underwent 228 sessions

of TACE were enrolled, and related clinical and laboratory data were analyzed.

Results:  In total, HBV reactivated in 33 (14.5%), remained stable in 152

(66.7%) and decreased in 43 (18.8%) sessions. Univariate analysis revealed that

sex and HBV DNA levels correlated with changes in HBV DNA status after TACE,

while hepatitis B e-antigen (HBeAg), prothrombin time and chemotherapeutic

agents were marginally significant factors. Multivariate analysis demonstrated

that the major factors that influenced the HBV DNA status were baseline HBV DNA

levels(P = 0.0002) and HBeAg (P = 0.0387). A comparison of the post-TACE

(30–90 days) liver function to the baseline revealed no significant

differences. The reactivation group has the highest rate of exacerbation (12.1%)

compared with the stable group (5.9%) and downregulation group (4.7%).

Conclusion:  HBV DNA changes after TACE included reactivated, decreased and

stable HBV DNA levels. Although HBV reactivation did not necessarily result in

exacerbation of liver damage and most HCC patients with Child–Pugh grade A and

B tolerated TACE well, careful post-procedure monitoring and managing is needed.

[Guest guest]

http://onlinelibrary.wiley.com/doi/10.1111/j.1872-034X.2011.00796.x/abstract

Changes in hepatitis B virus DNA levels and liver function after transcatheter

arterial chemoembolization of hepatocellular carcinoma

Xiang-Ming Lao1,2,†, Dian Wang1,†, Ming Shi1, Guipeng Liu3, Shengping Li1,

Rongping Guo1, Yunfei Yuan1, Minshan Chen1, Jinqing Li1, Yaqi Zhang1,*, Xiaojun

Lin1,*Article first published online: 29 MAR 2011

DOI: 10.1111/j.1872-034X.2011.00796.x

© 2011 The Japan Society of Hepatology

Issue

Hepatology Research

Volume 41, Issue 6, pages 553–563, June 2011

ABSTRACT

Aim:  Reports concerning changes in hepatitis B virus (HBV) status and liver

function in hepatocellular carcinoma (HCC) during or after transcatheter

arterial chemoembolization (TACE) have been rare and the results inconsistent.

The objective of this retrospective study was to evaluate these parameters in a

large cohort of HBV-related HCC patients.

Methods:  One hundred and seventy-two hepatitis B surface antigen positive HCC

patients with Child–Pugh grade A or B liver disease who underwent 228 sessions

of TACE were enrolled, and related clinical and laboratory data were analyzed.

Results:  In total, HBV reactivated in 33 (14.5%), remained stable in 152

(66.7%) and decreased in 43 (18.8%) sessions. Univariate analysis revealed that

sex and HBV DNA levels correlated with changes in HBV DNA status after TACE,

while hepatitis B e-antigen (HBeAg), prothrombin time and chemotherapeutic

agents were marginally significant factors. Multivariate analysis demonstrated

that the major factors that influenced the HBV DNA status were baseline HBV DNA

levels(P = 0.0002) and HBeAg (P = 0.0387). A comparison of the post-TACE

(30–90 days) liver function to the baseline revealed no significant

differences. The reactivation group has the highest rate of exacerbation (12.1%)

compared with the stable group (5.9%) and downregulation group (4.7%).

Conclusion:  HBV DNA changes after TACE included reactivated, decreased and

stable HBV DNA levels. Although HBV reactivation did not necessarily result in

exacerbation of liver damage and most HCC patients with Child–Pugh grade A and

B tolerated TACE well, careful post-procedure monitoring and managing is needed.